15.4.2019
EN
Official Journal of the European Union
C 139/51
Judgment of the General Court of 6 March 2019 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)
(Case T-321/18) (1)
(EU trade mark - Opposition proceedings - Application for EU word mark NOCUVANT - Earlier word marks NOCUTIL - Proof of genuine use - Article 47(2) of Regulation (EU) 2017/1001 - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation 2017/1001)
(2019/C 139/51)
Language of the case: English
Parties
Applicant: Serenity Pharmaceuticals LLC (Milford, Pennsylvania, United States) (represented by: J. Day, Solicitor)
Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė and H. O’Neill, acting as Agents)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Gebro Holding GmbH (Fieberbrunn, Austria) (represented by: M. Konzett, lawyer)
Re:
Action brought against the decision of the Second Board of Appeal of EUIPO of 8 March 2018 (Case R 584/2017-2), relating to opposition proceedings between Gebro Holding and Allergan, Inc.
Operative part of the judgment
The Court:
1.
Dismisses the action;
2.
Orders Serenity Pharmaceuticals LLC to pay the costs.
(1) OJ C 240, 9.7.2018.
Full & Egal Universal Law Academy